GlassScriptPhysician profile
Kelly E Felps
NPI 1205804366
$1,252.03
in general payments reported to CMS, 2019-2025
24 companies · $90.94 in 2025
The $90.94 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $57.26 · 2021: $381 · 2022: $194 · 2023: $243 · 2024: $130 · 2025: $90.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $232.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $175.43 | 2021-2023 | |
| Glaxosmithkline, LLC. | $104.43 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $89.54 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.89 | 2022-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $66.07 | 2022 | |
| Cranial Technologies, INC | $65.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $61.00 | 2021-2024 | Gardasil, Vaxelis, Gardasil 9 |
| Lilly USA, LLC | $47.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.74 | 2019 | |
| Currax Pharmaceuticals LLC | $30.17 | 2021-2025 | Contrave |
| Biohaven Pharmaceuticals, INC. | $29.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.82 | 2021 | |
| Tonix Medicines, INC. | $21.68 | 2025 | Tonmya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $21.38 | 2022 | |
| Genentech USA, INC. | $21.22 | 2020 | |
| Eisai INC. | $18.57 | 2021 | |
| Dexcom, INC. | $18.36 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $17.68 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $16.51 | 2025 | |
| Sanofi Pasteur INC. | $15.24 | 2019 | |
| Esperion Therapeutics, INC. | $14.07 | 2024 | Nexletol |
| Tactile Systems Technology INC | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Felps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.